The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis
Open accessAbstract
SQ109, a 1,2-diamine related to ethambutol, is currently in clinical trials for the treatment of tuberculosis, but its mode of action remains unclear. Here, we demonstrate that SQ109 disrupts cell wall assembly, as evidenced by macromolecular incorporation assays and ultrastructural analyses. SQ109 interferes with the assembly of mycolic acids into the cell wall core of Mycobacterium tuberculosis , as bacilli exposed to SQ109 show immediate inhibition of trehalose dimycolate (TDM) production and fail to attach mycolates to the cell wall arabinogalactan. These effects were not due to inhibition of mycolate synthesis, since total mycolate levels were unaffected, but instead resulted in the accumulation of trehalose monomycolate (TMM), the precursor of TDM and cell wall mycolates. In vitro assays using purified enzymes showed that this was not due to inhibition of the secreted Ag85 mycolyltransferases. We were unable to achieve spontaneous generation of SQ109-resistant mutants; however, analogs of this compound that resulted in similar shutdown of TDM synthesis with concomitant TMM accumulation were used to spontaneously generate resistant mutants that were also cross-resistant to SQ109. Whole-genome sequencing of these mutants showed that these all had mutations in the essential mmpL3 gene, which encodes a transmembrane transporter. Our results suggest that MmpL3 is the target of SQ109 and that MmpL3 is a transporter of mycobacterial TMM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Genes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544
Brennan, P. J., & Nikaido, H. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.000333 · Cited by 1,985
Global tuberculosis control 2010
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,262
Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis
Brennan, P. J. (2003) · Tuberculosis · doi:10.1016/s1472-9792(02)00089-6 · Cited by 884
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740 · cited 1×
“The inhibition of mycolic acid biosynthesis by drugs such as INH (64), peptidoglycan biosynthesis by betalactams (28), branching of cell wall arabinan synthesis by EMB (49, 62), and inhibition of the epimerization of ribose residues required for arabinan synthesis by the benzothiazinones (46) highlight the extreme vul…”
BackgroundRole of the Major Antigen of Mycobacterium tuberculosis in Cell Wall Biogenesis
Belisle, J. T., Vissa, V. D., Sievert, T., Takayama, K., Brennan, P. J., & Besra, G. S. (1997) · Science · doi:10.1126/science.276.5317.1420 · Cited by 734
The Envelope Layers of Mycobacteria with Reference to their Pathogenicity
Daffé, M., & Draper, P. (1997) · Advances in Microbial Physiology · doi:10.1016/s0065-2911(08)60016-8 · Cited by 730
Treatment for tuberculosis, guidelines for national programmes
Gyselen, E. A. (1994) · Health Policy · doi:10.1016/0168-8510(94)90025-6 · Cited by 708
Cited by
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
DeJesus, M. A., Gerrick, E. R., Xu, W., Park, S. W., Long, J. E., Boutte, C. C., Rubin, E. J., Schnappinger, D., Ehrt, S., Fortune, S. M., et al. (2017) · mBio · doi:10.1128/mbio.02133-16 · Cited by 668
Mycolic Acids: Structures, Biosynthesis, and Beyond
Marrakchi, H., Lanéelle, M.-A., & Daffé, M. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.11.011 · Cited by 623
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
Zhang, H., Li, D., Zhao, L., Fleming, J., Lin, N., Wang, T., Liu, Z., Li, C., Galwey, N., Deng, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2735 · Cited by 429
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
Makarov, V., Lechartier, B., Zhang, M., Neres, J., van der Sar, A. M., Raadsen, S. A., Hartkoorn, R. C., Ryabova, O. B., Vocat, A., Decosterd, L. A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303575 · Cited by 380
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 373
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
NTM drug discovery: status, gaps and the way forward
Wu, M.-L., Aziz, D. B., Dartois, V., & Dick, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.04.001 · Cited by 276
Discovery and Development of SQ109: A New Antitubercular Drug with a Novel Mechanism of Action
Sacksteder, K. A., Protopopova, M., Barry, C. E., Andries, K., & Nacy, C. A. (2012) · Future Microbiology · doi:10.2217/fmb.12.56 · Cited by 269
Self-citationThe Mycobacterial Cell Envelope--Lipids
Jackson, M. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021105 · Cited by 269
Discovery of a Siderophore Export System Essential for Virulence of Mycobacterium tuberculosis
Wells, R. M., Jones, C. M., Xi, Z., Speer, A., Danilchanka, O., Doornbos, K. S., Sun, P., Wu, F., Tian, C., & Niederweis, M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003120 · Cited by 267
“MmpL3, MmpL7 and MmpL8 were shown to export lipids such as trehalose monomycolate [30,31,32], phthiocerol dimycocerosate [33,34], and sulfolipid 1 [35] leading to the hypothesis that the MmpL proteins are lipid transporters.”
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target
Zhang, B., Li, J., Yang, X., Wu, L., Zhang, J., Yang, Y., Zhao, Y., Zhang, L., Yang, X., Yang, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.003 · Cited by 263
PfSETvs methylation of histone H3K36 represses virulence genes in Plasmodium falciparum
Jiang, L., Mu, J., Zhang, Q., Ni, T., Srinivasan, P., Rayavara, K., Yang, W., Turner, L., Lavstsen, T., Theander, T. G., et al. (2013) · Nature · doi:10.1038/nature12361 · Cited by 260
Stanley, S. A., Grant, S. S., Kawate, T., Iwase, N., Shimizu, M., Wivagg, C., Silvis, M., Kazyanskaya, E., Aquadro, J., Golas, A., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb300151m · Cited by 253
MmpL Genes Are Associated with Mycolic Acid Metabolism in Mycobacteria and Corynebacteria
Varela, C., Rittmann, D., Singh, A., Krumbach, K., Bhatt, K., Eggeling, L., Besra, G. S., & Bhatt, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.03.006 · Cited by 210
“The identification ofmmpL3 as an essential membrane protein-encoding gene involved in mycolate transport opens up new avenues for targeting this vital and under-exploited mycobacterial pathway for developing new anti-TB drugs, an opportunity highlighted by the identification of MmpL3 as the target of three drugs (La R…”
BackgroundResultInfluentialLi, W., Upadhyay, A., Fontes, F. L., North, E. J., Wang, Y., Crans, D. C., Grzegorzewicz, A. E., Jones, V., Franzblau, S. G., Lee, R. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03229-14 · Cited by 202
MmpL3 is the flippase for mycolic acids in mycobacteria
Xu, Z., Meshcheryakov, V. A., Poce, G., & Chng, S.-S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700062114 · Cited by 201
Probing the Mycobacterial Trehalome with Bioorthogonal Chemistry
Swarts, B. M., Holsclaw, C. M., Jewett, J. C., Alber, M., Fox, D. M., Siegrist, M. S., Leary, J. A., Kalscheuer, R., & Bertozzi, C. R. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3062419 · Cited by 184
Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052951 · Cited by 177
“Similarly, the M. tuberculosis inhibitors SQ109 [14,15,16] adamantly ureas [17,18], and benzimidazole [19] were identified following HTS campaigns and chemical lead optimization.”
BackgroundDirect Inhibition of MmpL3 by Novel Antitubercular Compounds
Li, W., Stevens, C. M., Pandya, A. N., Darzynkiewicz, Z., Bhattarai, P., Tong, W., Gonzalez-Juarrero, M., North, E. J., Zgurskaya, H. I., & Jackson, M. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00048 · Cited by 97
Imaging mycobacterial growth and division with a fluorogenic probe
Hodges, H. L., Brown, R. A., Crooks, J. A., Weibel, D. B., & Kiessling, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720996115 · Cited by 96
Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria
Fay, A., Czudnochowski, N., Rock, J. M., Johnson, J. R., Krogan, N. J., Rosenberg, O., & Glickman, M. S. (2019) · mBio · doi:10.1128/mbio.00850-19 · Cited by 65
Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic target
Adams, O., Deme, J. C., Parker, J. L., Fowler, P. W., Lea, S. M., & Newstead, S. (2021) · Structure · doi:10.1016/j.str.2021.06.013 · Cited by 63
Insights on How the Mycobacterium Tuberculosis Heme Uptake Pathway can Be Used as a Drug Target
Owens, C. P., Chim, N., & Goulding, C. W. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.109 · Cited by 50
Touchette, M. H., Van Vlack, E. R., Bai, L., Kim, J., Cognetta, A. B., Previti, M. L., Backus, K. M., Martin, D. W., Cravatt, B. F., & Seeliger, J. C. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00179 · Cited by 34
Transport of outer membrane lipids in mycobacteria
Touchette, M. H., & Seeliger, J. C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.01.005 · Cited by 33
Gupta, K. R., Gwin, C. M., Rahlwes, K. C., Biegas, K. J., Wang, C., Park, J. H., Liu, J., Swarts, B. M., Morita, Y. S., & Rego, E. H. (2019) · doi:10.1101/633768 · Cited by 1
Metadata
- Authors
- Tahlan, K., Wilson, R., Kastrinsky, D. B., Arora, K., Nair, V., Fischer, E., Barnes, S. W., Walker, J. R., Alland, D., Barry, C. E., & Boshoff, H. I.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-04
- Volume
- 56
- Issue
- 4
- Pages
- 1797-1809
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2155375392
- Cited by
- 504
- References
- 65
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.